What volumes would you treat and what dose constraints do you use for breast and lymphatic re-irradiation?

H&N cancer brachial plexus re-irradiation data, “Among patients with a Dmax greater than vs less than 106 Gy, the 1-year cumulative incidence of brachial plexopathy (BPP) was 42% vs 4% P = 0.005. V80 > 1cc (1-yr cumulative incidence BPP 34% vs 4% P = 0.03) and V90 > 0.3cc (32% vs 4%, P = 0.046) asso...

I have done in a few situations for palliation and favored 1.2 BID to mid-30s limited to the area of residual disease warning patients of the potential risk of plexopathy.